Imetelstat Combination Therapy

A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
36 patients (estimated)
Sponsors
Children's Oncology Group
Collaborators
Geron Corporation, National Cancer Institute (NCI)
Tags
Telomerase Inhibitor
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1964
NCT Identifier
NCT06247787

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.